BioCentury

8:00 AM GMT, Feb 9, 2009
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Aiming to be photogenic

Clinuvel Pharmaceuticals Ltd. spent the first half of this decade looking for a therapeutic application for its afamelanotide, which it knew worked as a photoprotectant and which the media had tagged as a potential tanning agent. In late 2005, the company finally came up with a focus on diseases provoked by ultraviolet light.

Now, Clinuvel has positive interim Phase III data in erythropoietic protoporphyria that it believes will get afamelanotide approved for the Orphan indication in 2010.

Erythropoietic protoporphyria (EPP) is caused by a deficiency in the enzyme ferrochelatase, which catalyzes protoporphyrin IX

Read the full 919 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.